Emerging microRNA Therapeutic Approaches for Cystic Fibrosis
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and remains the most common life-shortening diseases affecting the exocrine organs. The absence of this channel results in an imbalance of ion concentrations across the cell membrane an...
Main Authors: | Pauline Bardin, Florence Sonneville, Harriet Corvol, Olivier Tabary |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01113/full |
Similar Items
-
miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis
by: Pauline Bardin, et al.
Published: (2019-11-01) -
Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies
by: Fahad A. Almughem, et al.
Published: (2020-07-01) -
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis
by: Anna Esposito, et al.
Published: (2020-05-01) -
CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis
by: Jennifer L. Taylor-Cousar
Published: (2020-08-01) -
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
by: Giulia Amico, et al.
Published: (2019-11-01)